Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study
PaperCitations, authors & open-access status
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 79 citations, 2022 year and closed oa status.
79
Citations
2022
Year
closed
OA Status